Cardiff Oncology, Inc.
About Cardiff Oncology, Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company that leverages PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies for various cancers with unmet medical needs. The company focuses on targeting tumor vulnerabilities with treatment combinations of onvansertib, its oral and selective PLK1 inhibitor, and standard-of-care (SoC) therapeutics. The firm's clinical program pipeline focuses on indications such as RAS-mutated metastatic colorectal cancer (mCRC), investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma (mPDAC), small cell lung cancer (SCLC), metastatic triple negative breast cancer (mTNBC), and Chronic Myelomonocytic Leukemia (CMML). Geographically, it operates only in the United States.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Revenue FY2025
- $593.0K
- Net income
- -$45.9M
- Total assets
- $61.9M
- Market cap
- $102.6M
- Operating margin
- -9305.7%
- Net margin
- -8492.0%
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $488.0K
- Operating expenses
- $45.9M
- Operating income
- -$45.4M
- Income tax
- -$9.1M
- Net income
- -$41.4M
- EPS (basic)
- $-0.93
- EPS (diluted)
- $-0.93
Balance sheet
- Total assets
- $81.6M
- Current assets
- $77.4M
- Total liabilities
- $11.9M
- Current liabilities
- $10.4M
- Shareholders’ equity
- $69.7M
Cash flow
- Operating cash flow
- -$30.9M
- Investing cash flow
- $36.2M
- Financing cash flow
- -$5.3M
- Net cash flow
- $0
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $102.6M
- EPS (diluted)
- $-0.93
- Shares outstanding
- 68.4M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- May 22, 1997
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $45.9M in FY2025.
- Revenue grew 33% from FY2020 to FY2023.
- Trading 66% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review Cardiff Oncology, Inc..
Write a review
News about Cardiff Oncology, Inc.
News & sentiment via Polygon.io
